SUMMARY 604 Patients with atherothrombotic cerebral ischemic events (transient, 16%: or completed, 84%) referrable either to the carotid or to the vertebral-basilar circulation were entered into a double blind randomized clinical trial (AICLA) to determine whether aspirin (A) (1 g/day) or aspirin (1 g/day) + Dipyridamole (225 mg/day) (AD) would produce a significant reduction in the subsequent (3 years) occurrence of fatal and nonfatal cerebral infarction.
) referrable either to the carotid or to the vertebral-basilar circulation were entered into a double blind randomized clinical trial (AICLA) to determine whether aspirin (A) (1 g/day) or aspirin (1 g/day) + Dipyridamole (225 mg/day) (AD) would produce a significant reduction in the subsequent (3 years) occurrence of fatal and nonfatal cerebral infarction. Randomization produced remarkably comparable treatment groups and this good comparability was maintained throughout the study. Adherence to the protocol and drug compliance were excellent.
Side effects, particularly symptoms of peptic ulcer and hemorrhagic events were significantly (p< 0.03) more frequent in the two treatment groups containing aspirin.
With the exception of patients who withdrew from the study, each patient was followed for 3 years. At the end of the study, the number of fatal and nonfatal cerebral infarctions was 31 in the placebo (P) group, 17 in the A group and 18 in the AD group. Taking into account the duration of follow-up for each patient, these figures correspond to cumulative rates of 18% in the P group and 10.5% in each of the 2 active treatment groups. Analysis with the Mantel Method showed: 1) -A difference at the 6% level between the 3 groups and between P and AD; 2) -A difference at the 5% level between P and A; 3) -No difference between A and AD; 4) -A difference at the 2 % level between the P group and the two treated groups taken together (A + AD). Among other diseases occurring during the trial, the only significant difference concerned myocardial infarction, which was less frequent in the 2 treated groups (P< 0.05). Subgroup analysis failed to show a significant sex difference in the efficacy of aspirin.
It is concluded that, in patients comparable to those defined in the protocol, Aspirin (1 g) has a significantly beneficial effect in the secondary prevention of atherothrombotic cerebral infarction.
Stroke, Vol 14, No 1, 1983 DESPITE A DECLINE IN incidence in many developed countries, 1,2 stroke remains a major cause of death and one of the most disabling of diseases. 3 The majority of strokes are related to thrombus formation on atheromatous lesions leading to embolization or thrombosis in situ, with subsequent cerebral infarction. [3] [4] [5] [6] In many cases, atherothrombotic cerebral infarction is preceded by a transient ischemic attack (TIA) or a minor stroke, [4] [5] [6] [7] thus making secondary prevention feasible. Until recent years primary prevention was achieved mainly by treating arterial hypertension and the efficacy of this treatment is well established.
3 *" 10 Secondary prevention was based on anticoagulants and arterial surgery. However, the benefit of long-term anticoagulants has not been proven and that of arterial surgery is still debated and in any event, is not feasible in the majority of cases." These facts, together with the acknowledged role of platelets in arterial thrombosis, have led to the use of plateletinhibiting drugs. Dipyridamole, 12 clofibrate, 13 sulfinpyrazone 14 did not decrease the incidence of stroke recurrences. Several prospective trials have been performed with aspirin (table 10), but with conflicting results. [14] [15] [16] [17] [18] The aim of the "AICLA"* study was to determine in a double blind randomized clinical trial whether Aspirin (1 g/day) or Aspirin (1 g) + Dipyridamole (225 mg) would produce a significant reduction in the occurrence of fatal and nonfatal cerebral infarction after 3 years of follow-up. symptoms such as dizziness, loss of consciousness, diplopia, vertigo, or loss of memory were not acceptable. Eligibility criteria were reviewed for each patient by all participating neurologists.
Exclusions
The following patients were excluded: 8. Patients with residual deficits severe enough to preclude attendance at the outpatient clinic or in whom further deterioration would be easily appreciated.
9. Patients unwilling to consent to randomization.
Baseline Studies
The neurologic assessment at entry included an extensive documentation of the ischemic episode, which was referred to the carotid or vertebral-basilar territory, and classified as TIA, completed stroke (CS) or as a probable lacune. Cerebral angiography was optional. CT scan was not mandatory since it was not introduced in France until after the beginning of the trial. Past history, risk factors, and the cardio-vascular condition of the patients were assessed with as many details as possible. An ECG, a chest x-ray, and a series of analyses of blood chemistry and hematologic determinations were performed to exclude co-morbid conditions.
Allocation
As soon as baseline studies had been completed, the responsible neurologist decided upon the eligibility of the patient. If eligible, the patient was entered into a previously established randomization schedule, balanced for every 6 patients, and the trial medications were started immediately.
Drug Regimens
Patients were randomized to one of the three regimens throughout the study. Each regimen was taken three times a day and consisted of:
(1) a 330 mg acetyl salicylic acid capsule (A group) (2) a placebo capsule (P group) and (3) a 330 mg aspirin + 75 mg dipyridamole capsule (A-D group). Active drugs and placebo were identical in size, shape, weight and colour. Neither the patients nor their physicians were told to which regimen they had been assigned. In addition to this treatment, drugs were given as indicated in the management of the specific risk factors of hypertension, diabetes, and hyperlipidemia.
Compliance and Contamination
At each follow-up visit, patients were asked about their drug habits. Urine salicylate measurements were performed during the last 18 months of the trial, results remaining unavailable to the responsible neurologist.
A salicyluric index was defined as the number of positive results divided by the number of measurements. Its theoretical value is therefore zero in the placebo group and one in the A and AD groups. Patients were supplied with a list of drugs containing aspirin and of other antiplatelet drugs to be avoided. Acetaminophen was recommended as an analgesic.
Follow-up
Patients were re-evaluated at least every 4 months for 3 years. The general practitioners were kept informed at each visit and were asked to refer patients to hospital if an event was suspected. Similarly, the patients were advised to inform the responsible neurologist of any new symptoms. Detailed neurologic and cardiovascular examinations were performed, in particular blood pressure was taken in both arms in the sitting position. Compliance, contamination, and side effects of drugs were assessed. A new supply of drugs was given. Routine laboratory investigations and ECG were performed at least once a year. A meeting of all participating members was held every 4 months to review the files and discuss the interpretation of all new events.
Withdrawals
It was recognized at the outset that a number of patients might be withdrawn from the trial because of submission to surgery, removal from Paris, discontinuation of study drugs for more than 30 days a year, initiation of contaminating medications, occurrence of side effects, or of any disease which would be incompatible with the attendance at the outpatient clinic. It was also decided to consider as a cause of withdrawal any new event (such as atrial fibrillation) which, had it been present at entry, would have rendered the patient ineligible. Withdrawn patients had, as far as possible, the same follow-up as other patients. Those withdrawn because of ischemic stroke end-points received, for the most part, ticlopidine 750 mg daily. Those withdrawn because of myocardial infarction or pulmonary emboli received heparin followed by oral anticoagulation.
Events
The absolute end-points were fatal and nonfatal cerebral infarction occurring in the 3 years following inclusion. Cerebral infarction was diagnosed when a patient had a stroke with symptoms and signs persisting for more than 24 hours (completed stroke CS). The ischemic nature of the stroke was established clinically and with the usual ancillary investigations; after 1977 CONTROLLED TRIAL OF ASPIRIN AND DIPYRIDAMOLE/So^er et al.
this included CT scan. It is possible that before the introduction of the CT scan, a few patients with intracerebral hemorrhage might have been misdiagnosed as afflicted with infarction; however it was felt that, if a bias was thus introduced, it would be against aspirin rather than against placebo.
The occurrence of a cerebral infarction was interpreted as a failure of the test drug; the patient was therefore withdrawn but, as far as possible, had the same follow-up.
Detailed additional information was obtained about other diseases, particularly myocardial infarction. All deaths were documented and classified according to their cause, if possible by autopsy. It was decided, deliberately, not to take into account TIAs which, despite their well known importance as warning signs, bear little influence on the health of the patients.
Side-effects of drugs were documented with as much detail as possible.
Statistical Analysis
It was recognized that all study patients would not be in the trial for the same length of time, particularly because the occurrence of stroke is unpredictable and because the entry would occur at different times. Calculation of the relapse rate according to the number of patients either at the beginning or the end of the trial thus might have been under or overestimated. Therefore, it was felt necessary to take into account for each patient, in the outcome analysis, the time elapsed between the inclusion of the patient and the occurrence of an end-point. Since there were more than two treatment groups, it was decided to use the logrank (Mantel) test 21 to compare the evolution of the occurrence rates of the various pathological events between the 3 groups.
Appropriate parametric and nonparametric tests were used to analyze baseline characteristics at the onset and at the end of the trial in order to detect differences among the study groups.
Although open to some criticism 22 subgroup analysis was carried out to allow comparisons with results obtained in previous similar studies. 14 ' 18 Number of Patients When the protocol was established in 1974 a sample-size estimation of the number of patients was based on the assumption that the risk of cerebral infarction was 20% at 3 years. It was calculated that 200 patients would be required in each group to detect a 50% reduction in the treated groups with a type I error a of 0.05, and a type 6 error of 0.10.
Results

Enrollment
Four centers entered patients into the trial between 1 October 1975 and 1 December 1978. During this time, 604 patients were entered, accounting for one-fifth of all patients examined for strokes or TIA's in the involved centers. The main causes of exclusion in decreasing order of frequency were: strokes related to cardiac emboli, early deaths, severe strokes with no or little improvement, peptic ulcer, ischemic events leading to surgery, refusal of randomization, and prescription of anticoagulants.
Among the 604 patients of the study population, 204 were in the placebo group (P), 198 in the aspirin group (A) and 202 in the aspirin-dipyridamole group (AD).
Characteristics at Entry
The entry characteristics have been published in detail 20 and will therefore be briefly summarized. General characteristics (table 1) did not differ significantly between the 3 groups.
As far as risk factors and cardiovascular comorbidity are concerned (table 2) the only difference observed was in the duration of arterial hypertension be- fore the entry episode: 12 years in the P group, 10 in the A group and 9 in the AD group (p < 0.05). No difference was observed in the association of risk factors (table 3) .
The three treatment groups were also comparable with respect to the incidence of previous neurologic episodes, and to the characteristics of the ischemic event at entry (table 4) .
Randomization produced remarkably comparable treatment groups (only 2 differences at/? < 0.05 were observed among more than 100 baseline parameters). 19 Among the main characteristics of the study population (tables 2, 3, 4) it should be noted that the patients were mainly men (70%), of average age 63, with numerous risk factors, and that the entry episode was much more often a CS (84%) than a TIA (16%).
Cooperation and Compliance
Sixty-six patients (11%) were withdrawn from the trial for reasons not strictly related to health problems: 12 moved away, 8 were lost to follow-up and 46 gave poor cooperation (drugs were stopped more than 30 days a year by the patients or their physicians, or aspirin was added). No differences among treatment groups were observed for these withdrawals (table 5) .
Follow-up visits were regularly attended; among the 359 patients still present in the trial after 3 years, only 17 visits (out of 3231) were not performed.
Drug compliance was assessed by asking the patients about their drug habits: 78 patients (13%) said they stopped the drug less than 30 days a year (mean duration: 16 days); compliance was evaluated also by urine salicylate measurements. Results showed a remarkably high compliance with a salicyluria index of 0.09 in the P group, 0.90 in the A group and 0.87 in the AD group. Moreover 82% in the P group, 83% in the A group and 70% in the AD group always had the expected results.
Side Effects of the Drugs (table 6)
Forty-one patients (7% of the whole population and 17% of withdrawals) were withdrawn because of side effects of drugs. 6 were in the P Group, 17 in the A group and 18 in the AD group (p < 0.03). This difference is even more marked when only peptic ulcers, gastrointestinal bleeding and other hemorrhages are taken into account (p < 0.01). None of these complications was fatal. By contrast, the three treatment groups were comparable with respect to minor side effects not leading to withdrawal such as headache, dizziness, blurring of vision, vertigo, ill-defined abdominal pain, tinnitus, constipation, and pruritus.
Other Withdrawals (table 5) Two hundred and forty-five patients (41%) stopped taking the trial medication prior to the close of the study: 88 in the P group, 82 in the A group and 75 in the AD group.
Sixty-six patients (11%) had a cerebral infarction and they will be examined in detail further.
Thirty patients (5%) died of the following causes: ischemic stroke (5), cerebral hemorrhage (2), myocardial infarction (4), pulmonary embolism (4), sudden death (3), cancer (4), respiratory failure (3), cardiac failure (2), peritonitis (1), car accident (1), ruptured CONTROLLED TRIAL OF ASPIRIN AND DIPYRIDAMOLE/BowMer et al. (1) . No significant difference was observed between the 3 groups with respect to the number, the cause and the time of deaths (16 ± 10 months after inclusion). Forty-seven patients (8%) had various diseases which were considered as causes of withdrawal either because they would have constituted a reason for exclusion at entry -such as the development of atrial fibrillation, or because they were considered to have indications for anticoagulants (pulmonary embolism), or because they were afflicted with co-morbid conditions too severe to permit continuation in the trial (mainly cancer). The distribution of disorders other than vascular disease was comparable in the 3 groups whereas vascular diseases were less frequent in the 2 treated groups (p < 0.04).
Primary Results (fig. 1)
Sixty-six patients (5%) suffered a cerebral infarction during the trial and, of these, 5 died: 31 were in the P group, 17 in the A group, and 18 in the AD group. Taking into account the trial time for each patient, these figures correspond to cumulative rates of respectively 18%, 10.5%, and 10.5%. Analysis with the Mantel method 21 revealed a p < 0.06 difference between the 3 groups. Comparison of groups two by two showed:
1. A significant difference (p < 0.05) between aspirin and placebo.
2. A p < 0.06 difference between P and AD. 3. No significant difference between A and AD. 4. A significant difference (p < 0.02) between the placebo group and the two treatment groups taken together (A + AD).
The new ischemic stroke occurred more often in the carotid artery territory (61%) than in that of the vertebral-basilar arteries (39%) and was not significantly related to the territory of the entry episode (48% were in the same territory and 52% in a different one). It was usually severe since 5 patients died, 77% had major sequelae, and only 10% went on to a complete recovery.
Other Results
The 3 groups were comparable with respect to deaths, whatever the cause.
As far as other diseases are concerned (table 7) , only one significant difference was observed, namely a reduction in the occurrence rate of myocardial infarction in the two treated groups (p < 0.05). Since myocardial and cerebral infarction are both usually manifestations of arterial thrombosis in atheromatous vessels, when these events were grouped together, the difference was highly significant (p < 0.004) in favor of the two treated groups (P-42; A-20; AD-21).
Subgroup analysis is summarized in be seen that there is no significant sex difference but there was a trend favoring females ( fig. 2 ) in the A group and a suggestion of a trend favoring males in the AD group (fig 3) . The trend favoring females with aspirin alone loses much of its potential interest when the more favorable outlook for females in the placebo group is noted (fig. 4) .
Results according to the risk factors and to the characteristics of the ischemic episode at entry show differences between the A and the AD groups, although these 2 groups were similar with respect to the major events of the trial. Such differences were sometimes in favor of aspirin and sometimes in favor of AD. Thus in the subgroup of carotid strokes, recurrence rate was lower (p < 0.02) in the AD group (6%) than in the A group (17%), whereas in the vertebral-basilar subgroup the opposite was observed (5% in the A group, 13% in the AD group).
Risk factors were reassessed regularly and no significant difference was observed at the end of the trial between treatment groups (table 9). It should also be noted, that despite efforts to reduce risk factors, no significant decrease was observed after 3 years of follow-up.
Discussion
The design of the study differs in some respects from most of the other published trials of secondary preven- were included. By contrast, in the present study, 84% of patients had a completed stroke (CS) at entry and only 16% had TIA's. In the other large study, the Canadian trial, 62% of the entries were patients with TIA and 32% had mild to moderate residual stroke deficit. Abbreviations: TIA = transient ischemic attack; RIND = reversible ischemic neurologic deficit; CS = completed stroke; MI myocardial infarction; G = grams.
Other major differences include: 1. The absence of a placebo group in some previous studies. 1723 " 25 2. A smaller number of patients in all other studies (the only study of the same magnitude was the Canadian Study 14 with 585 patients as compared to 604 in the present study).
3. A shorter duration of follow-up (the mean duration in most studies was 24 months whereas in the present study, and one other trial 17 the duration in the study for each patient was 36 months.) 4. A difference in major end-points: in some of the other studies, major end-points included TIA's, CS and death whereas in this study the only major endpoint was cerebral infarction, whether fatal or not.
Results obtained in previous studies were conflicting: the association of aspirin with dipyridamole was not shown to be beneficial 17 
'
23_25 but it was never tested against placebo; aspirin was shown to significantly reduce me incidence of TIA's in the American study 16 and that of stroke and death in the Canadian study 14 but other studies failed to show benefit. Results of the present study confirm and extend in some respects the findings of the Canadian trial.
14 Although the difference between the 3 groups by the Mantel method did not reach the conventional 5% level, it was thought valid to carry on the analysis and to compare treatment groups two by two for the following reasons:
1. The significance level (p < 0.06) was very close to the conventional 5% level.
2. The protocol was adhered to most carefully. 3. The drug compliance was excellent. 4. The results were homogeneous and coherent. 5. The 3 groups were remarkably comparable at entry as well as during the entire duration of the trial.
The comparison of the placebo and aspirin groups showed a significant reduction (p < 0.05) of cerebral infarction in the aspirin group. In the AD group, the risk reduction was somewhat less marked (p < 0.06). Since no significant difference was observed between A and AD groups, they were joined in a single ' 'active treatment" group in which the risk reduction, compared to placebo, is significant at the 2% level. This CONTROLLED TRIAL OF ASPIRIN AND DJPYWDAMOLE/Bousser et til. 13 study therefore shows that in a population of patients with a majority of CS at entry, aspirin significantly decreases the recurrence rate of cerebral infarction and that by contrast to the PARIS study, 32 Dipyridamole contributes no additional beneficial antiplatelet effect.
It is important to note that in this study as well as in the Canadian study 14 the beneficial effect was obtained with a daily dose of 1-1.3 g aspirin. Much has recently been written about the inhibition by aspirin of the synthesis of both thromboxane A 2 by platelets and of Prostacyclin by the vessel wall and it has been suggested that doses of aspirin as low as 150 mg or even 40 mg every 2 or 3 days would produce a maximal inhibition of thrombosis, in that inhibition of prostacyclin by aspirin is of shorter duration than that of Thromboxane A 2 . [26] [27] [28] On the other hand, it is well established that the effect of aspirin on the bleeding time decreases with age;
29 it is therefore possible that doses required to prevent thrombosis in older and atheromatous patients such as those included in the Canadian and AICLA studies, might be much higher than those necessary in control subjects.
By contrast to other studies, 141617 the beneficial effect of aspirin on stroke recurrence was accompanied by a significant increase in such side effects as peptic ulcer and a variety of hemorrhagic complications. The increase in these recognized complications of aspirin was taken to add further confirmation to the evidence for good drug compliance. However, none of these side effects were fatal and their occurrence certainly did not outweigh the benefit of aspirin.
An important additional finding of this trial was the significant reduction of myocardial infarction in the A and AD group (p < 0.05) and a highly significant reduction (p < 0.004) when myocardial and cerebral infarction were assessed together. Although conflicting results have been observed in trials of secondary prevention of myocardial infarction by A and AD, 30 " 32 it is interesting to note that in two of these studies 30,32 a beneficial effect on cerebral infarction was observed.
Subgroup analysis was performed to allow for comparison with previous studies, such as the Canadian trial 14 in which the benefit of aspirin was restricted to men. A similar sex difference has been found in some models of experimental thrombosis 33 and in other clinical trials 15 ' 16 ' 34 but its cause remains obscure. Results of the present study failed to confirm this sex difference revealing in fact a trend in favor of benefit for women in the aspirin only and placebo groups but for men in the aspirin and dipyridamole group. The reason for this discrepancy remains unknown and more studies on the subject of sex differences are required before firm conclusions can be drawn.
Conclusion
Results of this study show a beneficial effect of aspirin (1 g) in the secondary prevention of atherothrombotic cerebral infarction thus extending the favorable results already obtained in patients with TIA's and confirming the benefit to patients with TIA and stroke obtained in the Canadian trial. No additional benefit was observed in the group receiving both aspirin and Dipyridamole. As is usual in such clinical trials, the results apply only to the study population identified and treated and should not be extended to all stroke or TIA patients. This study also showed significant decrease in the occurrence of myocardial infarction but failed to confirm sex difference in the efficacy of aspirin. One might hope that other studies in progress such as the ongoing United Kingdom trial will help to answer questions raised by the variations in the results of the trials to date. 35 It remains imperative to obtain data on the optimal dose of aspirin.
